Gilead Sciences (Brazil) Top Management
GILD34 Stock | BRL 287.56 4.47 1.58% |
Gilead Sciences employs about 31 people. The company is managed by 9 executives with a total tenure of roughly 16 years, averaging almost 1.0 years of service per executive, having 3.44 employees per reported executive. Analysis of Gilead Sciences' management performance can provide insight into the company performance.
Daniel ODay Chairman Chairman of the Board, CEO |
Andrew Dickinson President Executive Vice President - Corporate Development and Strategy |
Gilead |
Gilead Sciences Management Team Effectiveness
The company has return on total asset (ROA) of 0.1045 % which means that it generated a profit of $0.1045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.216 %, meaning that it generated $0.216 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Gilead Sciences Workforce Comparison
Gilead Sciences is rated # 5 in number of employees category among its peers. The total workforce of Drug Manufacturers - Major industry is currently estimated at about 9,783. Gilead Sciences adds roughly 31.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers - Major industry.
The company has Profit Margin (PM) of 0.17 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.4 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.4. Gilead Sciences Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Gilead Sciences Price Series Summation is a cross summation of Gilead Sciences price series and its benchmark/peer.
Gilead Sciences Notable Stakeholders
A Gilead Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gilead Sciences often face trade-offs trying to please all of them. Gilead Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gilead Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Daniel ODay | Chairman of the Board, CEO | Profile | |
Andrew Dickinson | Executive Vice President - Corporate Development and Strategy | Profile | |
Johanna Mercier | Chief Commercial Officer | Profile | |
Deborah Telman | Gen Affairs | Profile | |
Jyoti Mehra | Ex HR | Profile | |
Jacquie CFA | VP Relations | Profile | |
Diane Wilfong | Corp VP | Profile | |
Michael Quigley | VP Biology | Profile | |
Linda Higgins | VP Innovation | Profile |
About Gilead Sciences Management Performance
The success or failure of an entity such as Gilead Sciences often depends on how effective the management is. Gilead Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gilead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gilead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. GILEAD DRN operates under Drug Manufacturers - Major classification in Brazil and is traded on Sao Paolo Stock Exchange. It employs 11000 people.
Please note, the presentation of Gilead Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gilead Sciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Gilead Sciences' management manipulating its earnings.
Gilead Sciences Workforce Analysis
Traditionally, organizations such as Gilead Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gilead Sciences within its industry.Gilead Sciences Manpower Efficiency
Return on Gilead Sciences Manpower
Revenue Per Employee | 880M | |
Revenue Per Executive | 3B | |
Net Income Per Employee | 148.1M | |
Net Income Per Executive | 510.2M |
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
CEOs Directory Screen CEOs from public companies around the world | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |